Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc. (Nasdaq: FHTX) is a clinical-stage biotechnology company developing medicines that target the chromatin regulatory system to correct abnormal gene expression, primarily in genetically defined cancers. Its small-molecule approaches include enzyme inhibitors, protein degraders and… From the company’s description.
Over the twelve months to Jun 30, 2026, Foghorn Therapeutics Inc. reported revenue of $36.74M, up 52.0% from a year earlier, and a net loss of $64.58M. Its operating margin was −198.0%, and operations used $84.24M in cash. In fiscal 2025, it reported revenue of $30.91M, up 36.8% from fiscal 2024, and a net loss of $74.28M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Foghorn Therapeutics Inc. does
In the company’s own words
Foghorn Therapeutics Inc. (Nasdaq: FHTX) is a clinical-stage biotechnology company developing medicines that target the chromatin regulatory system to correct abnormal gene expression, primarily in genetically defined cancers. Its small-molecule approaches include enzyme inhibitors, protein degraders and transcription-factor disruptors, with research also exploring applications beyond oncology. Foghorn’s Gene Traffic Control platform supports target identification and validation, drug discovery and biomarker development. Its pipeline includes programs targeting SMARCA2, CBP, EP300 and ARID1B; the lead candidate, oral SMARCA2 inhibitor FHD-909, is in a Phase 1 trial for advanced solid tumors with SMARCA4 mutations, with non-small cell lung cancer as the primary patient population. Through its collaboration with Eli Lilly, the companies are advancing oncology programs, including the SMARCA2 program, under a U.S. co-development and co-commercialization agreement. Foghorn has more than seven programs and had 106 employees as of December 31, 2025. Its website is https://www.foghorntx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1822462
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Foghorn Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Foghorn Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Foghorn Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Foghorn Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Foghorn Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”